The ototoxic effects of cisplatin in a Sprague-Dawley rat model were evaluated by recordings of auditory brainstem responses (ABR) and transiently evoked otoacoustic emissions (TEOAEs). The ABR responses were evoked from alternating clicks and 8, 10, 12, 16, 20 and 30 kHz tone pips in a range from 40 to 100 dB SPL range. The TEOAEs were recorded with a non-linear protocol, and were evoked by a ...

UNLABELLED School learning can be hampered if there are defects on the central auditory process. Since those with auditory deficiency can be rehabilitated, it is fundamental that we identify them. Otoacoustic emissions test has low cost and operational ease. STUDY DESIGN clinical and experimental. AIM to study the relationship between school learning and transient otoacoustic emission suppr...

In immature rodent brain, the glutamate receptor agonist N-methyl-D-aspartate (NMDA) is a potent neurotoxin. In postnatal day (PND)-7 rats, intrastriatal injection of 25 nmol of NMDA results in extensive ipsilateral forebrain injury. In this study, we examined alterations in high-affinity [3H]glutamate uptake (HAGU) in NMDA-lesioned striatum. HAGU was assayed in synaptosomes, prepared from lesi...

Contralateral stimulation of the auditory system causes changes in levels of otoacoustic emissions. The main objective of this study was to determine the changes in the level of distortion product otoacoustic emissions for contralaterally presented unmodulated broad-band noise, or amplitude modulated broad-band noise. Two types of modulating signal were used in the investigations (sine or recta...

Suppression of ipsilateral distortion product otoacoustic emissions (DPOAEs) by contralateral noise is used in humans and animals to assay the strength of sound-evoked negative feedback from the medial olivocochlear (MOC) efferent pathway. However, depending on species and anesthesia, contributions of other feedback systems to the middle or inner ear can cloud the interpretation. Here, contribu...

background: contralateral axillary metastasis (cam) is a rare entity in patients with breast cancer which can occur during the primary breast cancer or its follow-up. different treatment modalities include surgery, radiotherapy, and chemotherapy, but there is no agreement on them. in our review, we found 12 series with available data, 82 patients with synchronous or metachronous contralateral a...